Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourStrong Bearish
15 minStrong Bearish
5 minStrong Bullish
Daily trend turns up above $3.10
Key levels
Resistance$2.24
Resistance$1.69
Support$1.30
Latest news & SEC filings
ProductAdagene finishes patient sign-up for mid-stage muzastotug study
ProductAdagene finishes enrolling patients in Phase 2 trial of muzastotug for MSS CRC lacking liver metastases
ProductAdagene begins Phase 1 dosing of muzastotug with Incyte's INCA33890
All ADAG news →Adagene is a clinical-stage biopharmaceutical company that discovers and develops antibody-based cancer therapies. Its operations are conducted mainly through subsidiaries in China and the United States. The company develops novel antibody candidates using its proprietary platforms, with a focus on immuno-oncology treatments.
Based on the company's 20-F filed Apr 1, 2026.
Nasdaq · Healthcare
SEPT Low Target
$7.00
SEPT Mid Target
$9.00
SEPT High Target
$10.00
Analyst Consensus
$9.00
Thesis
Describe your strategy in plain words, then scan, alert, backtest and paper trade it on ADAG with SEPT’s own market data.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$9.00
24
Moat Score
NONE
5/9
Piotroski Score
-2.8
Altman Z-Score
Insider Signal
NEUTRAL
1 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
MEDIUM
Signal: NEUTRAL
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Tam Man Kin | director officer | Buy | 2,000 | $6K | Sep 23, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See Smart Money Data →Revenue YoY
7332.8%
3yr Revenue CAGR
-6.2%
EPS Growth YoY
49.15%
FCF Growth YoY
47.3%
Revenue Trend
ACCELERATING
Recent off-exchange (dark pool) prints for ADAG: size, dollar value and side. One of the data views on SEPT, alongside its own pressure bars, swings, volume spike levels and key levels.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:00 | $1.60 | 3,315 | $$5K | MIDPOINT |
| 20:59:37 | $1.61 | 1,100 | $$2K | BUY |
| 20:45:31 | $1.45 | 1,600 | $$2K | SELL |
| 20:40:52 | $1.46 | 1,400 | $$2K | SELL |
| 20:40:12 | $1.49 | 1,200 | $$2K | SELL |
5 dark pool trades shown · $$13K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for Adagene Inc. (ADAG) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...
Describe your strategy in plain words. SEPT scans, alerts, backtests and paper trades it on its own market data. SEPT provides tools only and does not tell you what to buy or sell.
Try SEPT Free for 7 Days →Adagene Inc. (ADAG) is at $1.52, down 5.00% (-$0.08) at the Nov 17, 2026 close.
Latest ADAG news — Nov 9, 2026: Adagene finishes patient sign-up for mid-stage muzastotug study · Nov 9, 2026: Adagene finishes enrolling patients in Phase 2 trial of muzastotug for MSS CRC lacking liver metastases
The average analyst price target for ADAG is $9.00, ranging from $7 to $10, based on 3 analysts.
Analyst ratings for ADAG: 1 Buy, 2 Hold, 0 Sell — consensus Hold.
ADAG last reported on Aug 12, 2026: EPS -$0.23 vs -$0.22 expected — a miss of 4.5%.
Support: $1.30. Resistance: $1.69, $2.24, $2.78.
Insider activity: NEUTRAL, 1 buys and 0 sells in the last 90 days.
Nov 9, 2026: Adagene finishes patient sign-up for mid-stage muzastotug study · Nov 9, 2026: Adagene finishes enrolling patients in Phase 2 trial of muzastotug for MSS CRC lacking liver metastases · Oct 28, 2026: Adagene begins Phase 1 dosing of muzastotug with Incyte's INCA33890